Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... Forward-Looking Statements This news release contains forward-looking statements that are ... The scientific information discussed in this news release related to our product candidates is preliminary ... the scientific information discussed in this news release relating to new indications for our products is ...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

... by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung ... This press release includes forward-looking statements that involve ... treatment of the indications noted in this press release or any other indication, determinations by ...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

... today for INTUNIV(TM) (guanfacine) Extended release from the Food and Drug Administration (FDA). This ... study of guanfacine extended release in children and adolescents with ... F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with ADHD: a ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... Disclaimer The foregoing release contains forward-looking statements that can be ... is providing the information in this press release as of this date and does not undertake any ... statements contained in this press release as a result of new information, future events or ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... statements set forth in this press release speak only as of the date of this press release. ... that occur after the date hereof. This press release and prior releases are available at ... is not incorporated by reference into this press release and is included as an inactive textual reference ...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... Except for historical information, this news release may contain forward-looking statements that ... Endo Forward-Looking Statements This press release contains forward-looking statements within the ... The forward-looking statements in this press release are qualified by these risk factors. These are ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... . Forward-Looking Statements This news release contains forward-looking statements that are ... The scientific information discussed in this news release related to our product candidates is preliminary ... the scientific information discussed in this news release relating to new indications for our products is ...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

... USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of ... is a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole ... Forward Looking Statements This press release contains forward-looking statements within the ...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

... Litigation Reform Act of 1995 This press release contains forward-looking statements related to ... any forward-looking statements contained in this release as a result of new information, future events or ... UCB Forward-looking Statement This press release contains forward-looking statements based on ...

Spherix Announces Positive Phase 2 Study Results

... . Forward-Looking Statements This release contains forward-looking statements which are ... release. We undertake no obligation to publicly release the results of any revisions to these ... circumstances that occur after the date of this release or to reflect the occurrence of unanticipated ...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... Forward-Looking Statements This press release contains "forward-looking statements" within the ... of the forward-looking statements in this press release may turn out to be wrong. They can be affected by ... differ materially from those set forth in this release due to the risks and uncertainties inherent in ...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

... by the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. ... Statements Statements in this press release regarding management's future expectations, ... is providing the information in this press release as of this date and assumes no obligations to ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract. ... at www.dorbiopharma.com . This press release contains forward-looking statements that reflect ...

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

... . Any statements contained in this press release referring to future events or other ... of example, statements contained in this press release related to the anticipated design of future ... ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... is available at www.lilly.com . This press release contains forward-looking statements about Amylin ... from those discussed or implied in this press release due to a number of risks and uncertainties, ... clinical data analyses mentioned in this press release not being predictive of real-world experience; or ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... Afinitor. Disclaimer The foregoing release contains forward-looking statements that can be ... is providing the information in this press release as of this date and does not undertake any ... statements contained in this press release as a result of new information, future events or ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... poliglumex in tumor tissue with continual slow release of the active agent, paclitaxel," noted Jack ... by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung ... This press release includes forward-looking statements that involve ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. ... Statements Statements in this press release regarding management's future expectations, ... is providing the information in this press release as of this date and assumes no obligations to ...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

... Pharma. The text of Celtic Pharma's press release is as follows: Celtic Pharma Announces ... Statements Certain statements in this press release that are not historical facts, including ... herein, the matters discussed in this press release are forward-looking statements that involve risks ...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... statements set forth in this press release speak only as of the date of this press release. ... that occur after the date hereof. This press release and prior releases are available at ... is not incorporated by reference into this press release and is included as an inactive textual reference ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... statements set forth in this press release speak only as of the date of this press release. ... that occur after the date hereof. This press release and prior releases are available at ... is not incorporated by reference into this press release and is included as an inactive textual reference ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... statements set forth in this press release speak only as of the date of this press release. ... that occur after the date hereof. This press release and prior releases are available at ... is not incorporated by reference into this press release and is included as an inactive textual reference ...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

... Imaging, Perceptive Informatics. "With the release of the RECIST 1.1 toolset Perceptive Informatics ... visit www.PAREXEL.com . This release contains "forward-looking" statements regarding ... The forward-looking statements in this release involve a number of risks and uncertainties. The ...

CuraGen to Present CR011-vcMMAE Data at ASCO

... the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. ... Statements Statements in this press release regarding management's future expectations, ... is providing the information in this press release as of this date and assumes no obligations to ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... Information. Disclaimer The foregoing release contains forward-looking statements that can be ... any of the existing products referred to in this release will be approved for any additional indications ... is providing the information in this press release as of this date and does not undertake any ...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

... visit www.PAREXEL.com . This release contains "forward-looking" statements regarding ... The forward-looking statements in this release involve a number of risks and uncertainties. The ... forward-looking statements included in this press release represent the Company's estimates as of the date ...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

... Statements Certain statements in this press release contain forward-looking statements that involve a ... events. Forward-looking statements in this press release include statements regarding ViroPharma's ... statements contained in this press release may become outdated over time. ViroPharma does ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... version of the journal, tapentadol immediate release (IR) tablets provided patients with equivalent ... 20, 2008, the FDA approved tapentadol immediate release tablets for the relief of moderate to severe ... It is also being developed in an extended release formulation for chronic pain. Study Design ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... previously announced by the company in a press release on February 3, 2009 as well as new information ... . Forward-Looking Statements This news release contains forward-looking statements within the ... and other information included in this press release are based on information available to InterMune ...

Spherix Reports First Quarter 2009 Earnings

... . Forward-Looking Statements This release contains forward-looking statements which are ... release. We undertake no obligation to publicly release the results of any revisions to these ... circumstances that occur after the date of this release or to reflect the occurrence of unanticipated ...

Spherix Elects New Independent Director, and Elects Chairman of the Board

... . Forward-Looking Statements This release contains forward-looking statements which are ... release. We undertake no obligation to publicly release the results of any revisions to these ... circumstances that occur after the date of this release or to reflect the occurrence of unanticipated ...

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

... Statements Statements included in this press release that are not a description of historical facts ... materially from those set forth in this press release due to the risks and uncertainties inherent in ... no obligation to revise or update this press release to reflect events or circumstances after the date ...

Tris Pharma Announces Acceptance of Its First Two NDAs

... - First ever 24 hour oral liquid sustained release formulation submitted to the FDA - Validates ... the need to swallow pills by providing sustained release in liquids, chewable tablets, and films - ... as alternative to current twice-a-day immediate release tablet SOUTH BRUNSWICK, N.J., May 13 ...

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

... development. Statements in this press release that are not strictly historical facts are ... Exchange Commission. The statements in this press release are made as of today, based upon information ... The information contained in this press release does not necessarily reflect the position or the ...

Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting

... about the use of tapentadol extended release tablets to treat patients with chronic low back ... J&JPRD continues to study tapentadol extended release formulation for chronic pain, and a New Drug ... The following posters on tapentadol extended release data will be presented at the 2009 APS meeting: ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

... (GAM) technology to locally stimulate the release of platelet-derived growth factor-B protein ... approaches benefiting from sustained localized release of therapeutic proteins and other agents. For ... fact, the matters discussed in this press release are forward looking and reflect numerous ...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

... visit www.PAREXEL.com . This release contains "forward-looking" statements regarding ... The forward-looking statements in this release involve a number of risks and uncertainties. The ... forward-looking statements included in this press release represent the Company's estimates as of the date ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... The statements contained in this media release that are not purely historical are ... amended. Forward-looking statements in this media release include statements regarding our expectations, ... forward-looking statements included in this media release are based upon information available to us as of ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... and trade names referred to in this press release are the property of their respective owners. ... Statements Statements contained in this press release that are not historical information are ... ev3 undertakes no obligation to publicly release the results of any revisions to these ...

Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments

... visit www.PAREXEL.com . This release contains "forward-looking" statements regarding ... The forward-looking statements in this release involve a number of risks and uncertainties. The ... forward-looking statements included in this press release represent the Company's estimates as of the date ...